Gomes-da-Silva LC - Search Results

1

Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.

Gomes-da-Silva LC, Simões S, Moreira JN. Gomes-da-Silva LC, et al. Cell Mol Life Sci. 2014 Apr;71(8):1417-38. doi: 10.1007/s00018-013-1502-2. Epub 2013 Nov 13. Cell Mol Life Sci. 2014. PMID: 24221135 Free PMC article. Review.

2

Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.

Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN. Gomes-da-Silva LC, et al. Acc Chem Res. 2012 Jul 17;45(7):1163-71. doi: 10.1021/ar300048p. Epub 2012 May 8. Acc Chem Res. 2012. PMID: 22568781

3

Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.

Gomes-da-Silva LC, Santos AO, Bimbo LM, Moura V, Ramalho JS, Pedroso de Lima MC, Simões S, Moreira JN. Gomes-da-Silva LC, et al. Int J Pharm. 2012 Sep 15;434(1-2):9-19. doi: 10.1016/j.ijpharm.2012.05.018. Epub 2012 May 19. Int J Pharm. 2012. PMID: 22617794

4

Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform.

Gomes-da-Silva LC, Fernández Y, Abasolo I, Schwartz S Jr, Ramalho JS, Pedroso de Lima MC, Simões S, Moreira JN. Gomes-da-Silva LC, et al. Nanomedicine (Lond). 2013 Sep;8(9):1397-413. doi: 10.2217/nnm.12.174. Epub 2013 Feb 8. Nanomedicine (Lond). 2013. PMID: 23394132

5

Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.

Gomes CP, Gomes-da-Silva LC, Ramalho JS, de Lima MC, Simões S, Moreira JN. Gomes CP, et al. Curr Gene Ther. 2013 Jun 1;13(3):189-201. doi: 10.2174/1566523211313030004. Curr Gene Ther. 2013. PMID: 23531193

6

Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.

Gomes-da-Silva LC, Ramalho JS, Pedroso de Lima MC, Simões S, Moreira JN. Gomes-da-Silva LC, et al. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):356-64. doi: 10.1016/j.ejpb.2013.04.007. Epub 2013 May 7. Eur J Pharm Biopharm. 2013. PMID: 23659854

7

Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.

Fonseca NA, Gomes-da-Silva LC, Moura V, Simões S, Moreira JN. Fonseca NA, et al. J Control Release. 2014 Dec 28;196:122-31. doi: 10.1016/j.jconrel.2014.09.024. Epub 2014 Oct 11. J Control Release. 2014. PMID: 25305563

8

Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.

Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Gregório AC, Valério-Fernandes Â, Gomes-da-Silva LC, Rosa MS, Moura V, Ramalho-Santos J, Simões S, Moreira JN. Fonseca NA, et al. Biomaterials. 2015 Nov;69:76-88. doi: 10.1016/j.biomaterials.2015.08.007. Epub 2015 Aug 6. Biomaterials. 2015. PMID: 26283155

9

Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment.

Gierlich P, Mata AI, Donohoe C, Brito RMM, Senge MO, Gomes-da-Silva LC. Gierlich P, et al. Among authors: gomes da silva lc. Molecules. 2020 Nov 14;25(22):5317. doi: 10.3390/molecules25225317. Molecules. 2020. PMID: 33202648 Free PMC article. Review.

10

Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity.

Donohoe C, Senge MO, Arnaut LG, Gomes-da-Silva LC. Donohoe C, et al. Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188308. doi: 10.1016/j.bbcan.2019.07.003. Epub 2019 Aug 8. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31401103 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters